Nanion Starts Shipping the SyncroPatch 384 Patch Engine - a Revolutionary Instrument for Giga-Seal, Automated Patch Clamp-Based Ion Channel Drug Screening
The SyncroPatch 384PE is the high quality, automated patch clamp system able to finally thrust gold standard electrophysiology from secondary to primary ion channel drug screening. Allowing for up to 20,000 data points per day, it is the most efficient platform on the market for high quality, ion channel recordings. This efficiency is primarily due to fully parallel measurements from 384 cells, the 384-channel pipettor, and an exceptionally efficient control and analysis software. Both hardware and software have been fully tested and validated with leading players in industrial ion channel drug development to provide optimum performance in true HTS for ion channel screening.
Dr. Niels Fertig, CEO of Nanion says:
“The SyncroPatch 384PE is a landmark in the history of automated patch clamping. It follows a completely revolutionary concept: a truly modular and HTS-capable automated patch clamp device that will integrate into your existing or planned screening process line, rather than being a closed, stand-alone system. No other platform on the market is capable of recording 384 to 768 cells in parallel, let alone with giga-seals. In development, we have carefully listened to key customers from industrial pharma high throughput screening laboratories to fulfil their requirements of HTS-settings. We are extremely excited and enthusiastic about our new platform, and so are the first customers who recently invested in several SyncroPatch PE instruments. We are happy to announce that we are now taking orders for delivery in 2013 of this maturely developed and fully validated platform.“
The SyncroPatch 384PE has successfully been validated with a wide variety of different cell types and ion channels, with consistently high performance regarding seal quality and stability. The excellent success rates and cell-stability promote efficient and reliable drug screening, thus minimizing the need of replicate experiments. The SyncroPatch 384PE is now fully available for sale, with the first systems being shipped during the coming month.
Nanion Technologies GmbH is a German Private Limited Company and was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and globally established three highly successful automated patch clamp instruments as enabling tools for sophisticated and high throughput applications for ion channel research and drug discovery.
Nanion recently launched the CardioExcyte 96, for cardiac safety screening, and the SURFE2R N96, a device for parallel membrane transporter protein recordings.
Niels Fertig, CEO, Phone: +49 89 2189 97972, Email: firstname.lastname@example.org, Web: www.nanion.de
Cecilia Farre, Marketing Director, Phone: +49 89 2189 979 73, Email: Cecilia.Farre@nanion.de
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nanion Starts Shipping the SyncroPatch 384 Patch Engine - a Revolutionary Instrument for Giga-Seal, Automated Patch Clamp-Based Ion Channel Drug Screening here
News-ID: 271253 • Views: 2034
More Releases from Nanion Technologies
Nanion Introduces New Product Family: CardioExcyte 96 for Cardiac Toxicity Profi …
Munich, Germany, September 12, 2013; The CardioExcyte 96 is a high resolution device recording contractility in intact cardiomyocyte networks utilizing non-invasive impedance measurements. The system allows cost-efficient, early compound safety profiling using stem cell-derived cardiomyocytes, freshly dissociated cardiomyocytes or beating 3D-cell clusters. Cardiac safety assessment is a vital part of drug development since late withdrawals of compound candidates, due to heart liability issues such as ventricular arrhythmia, are very
Nanion Introduces NPC-Certified Cell Lines
Munich, Germany, November 08, 2012; Nanion’s automated patch clamp platforms are known for their high cell compatibility, even for primary cells and stem cells. Nanion now introduces “Nanion Approved Cells”, where commercially available cell lines from several providers have been evaluated and certified based on cell and platform performance. The approved cells can be directly purchased through Nanion, so that Nanion’s customers get a complete package of APC platform and
Nanion Acquires the SURFE2R Technology for Transporter Protein Analysis
Nanion acquires the well-established SURFE2R technology, allowing state-of-the-art measurements of transporter protein activity and function. The SURFE2R technology is an excellent enhancement to Nanion’s existing products which until now covered ion channels and nanopores. Nanion Technologies is one of the leading providers of high quality automated patch clamp systems. Nanion’s efficient and versatile products drastically improve the data output in patch clamp-based ion channel screening, safety testing and scientific research. Since
Nanion Introduces the Orbit 16 – a Pioneering Device for Parallel Lipid Bilaye …
Munich, Germany, February 23, 2012; Today, Nanion announces the introduction of a completely new product line for efficient analysis of bilayer-reconstituted ion channels and nanopores. The first of these, the Orbit 16, allows for automated formation of, and recordings from 16 bilayers in parallel, combining efficient data generation and ultra-high data quality. The Orbit 16 takes the pain out of bilayer recordings and facilitates efficient data generation through 16
More Releases for Patch
Global Skin Patch Market Research Report
This report studies the global Skin Patch market status and forecast, categorizes the global Skin Patch market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report GSK Teikoku Seiyaku Johnson & Johnson Novartis AG Mylan N.V. Bayer Lingrui Sanofi Teva Pharmaceutical Industries Luye
Paw Patch Pastries' New Location
San Francisco, CA – Paw Patch Pastries and Pet Boutique, the provider of upscale pet treats, custom cakes, and adorable toys, has moved to the fitting “Dog Patch” area of San Francisco. The new location at 701 Pennsylvania Avenue was officially open for business on August 2. This unique boutique is the pawfect spot to pamper your pooch or kitty, offering daily baked goods and sweet treats as well as
Transdermal Patch Market Report 2018: Segmentation by Product (Fentanyl Transder …
Global Transdermal Patch market research report provides company profile for Actavis, Mundipharma, Henan Lingrui Pharmaceutical, Changzhou Siyao, Rfl Pharmaceutical, Hisamitsu Pharmaceutical, Novartis, Johnson & Johnson, Teikoku Pharma, Mylan and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018
Transdermal Patch Market Transdermal Patch Clinical Pipeline Report 2022
For Report Sample Contact: email@example.com or +91-11-47067990 Report Table of Contents Introduction to Transdermal Patch Classification of Transdermal Patches 2.1 Single/ Multiple-Layer Drug-in-Adhesive 2.2 Reservoir Transdermal Patches 2.3 Matrix Based Transdermal Patches 2.4 Vapor Patch 2.5 Active and Passive Patch Why There Exist Need for Transdermal Patches? Mechanism of Transdermal Patch Drug Delivery 4.1 Properties of Transdermal Therapeutics 4.2 Components of Transdermal Patch 4.3
Transdermal Patch Market & Pipeline Insight 2015
Technological progress is continuously increasing allowing pharmaceutical companies to develop newer products with higher pharmacological benefits. Transdermal patches are extension of their continuous efforts due to which several patients have been able to improve quality of life. This market segment has yet to be tapped as only few disease indications are being covered under their treatment. Pharmaceutical companies are increasing their investments in research and development segment to introduce novel
Global Insulin Patch Market Opportunity Analysis
Transdermal drug delivery is one of the oldest methods that have been used by physicians to alleviate patients medical condition. Patches are recent inventions of pharmaceutical companies for those patient populations who can’t be administered with conventional drugs. They are applied over the skin from which drug is released in controlled manner followed by entry into the body. Topical drugs are also applied on skin but their effect is local